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Purpose: This study assesses the incidence of distal bone metastases in palliative radiotherapy (RT) pa-
tients.
Material and methods: All courses of RT for bone metastases from 2007–2011 for patient living in British
Columbia (BC) were identiﬁed in a provincial RT programme. Treated bone metastases (BoM) were ca-
tegorized as distal if the BoM was located within or distal to the elbow or knee. Patients were grouped by
primary tumour site as breast, lung, prostate gastrointestinal, haematological, melanoma, and other. The
incidence of distal bone metastases and associations with primary tumour types were determined.
Results: From 2007 to 2011, 8008 patients were treated with 16,277 courses of RT, of which 425 (3%)
were courses of RT for distal BoM. The incidence of distal BoM in decreasing order by primary tumour
type was melanoma (5%), haematological (3%), lung (2%), other (2%), prostate (2%), breast (1%) and
gastrointestinal (1%). Distal BoM where more commonly identiﬁed in the lower extremity (87%,
po0.001). Single fraction RT was used more commonly for distal vs non-distal BoM (66% vs. 49%;
po0.001).
Conclusion: The incidence of distal BoM among patients treated with palliative RT was 3% and most
commonly identiﬁed in patients with melanoma and haematological malignancies.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metastasis to the bone is a common complication of breast,
lung, prostate, gastrointestinal, haematological, melanoma, and
other tumours [1–3]. In many patients with primary breast,
prostate and lung primary tumours, bone metastases (BoM) are
signs associated with the presence of disseminated disease [4].
These metastases to the bone will usually result in patients ex-
periencing pain which is often palliated using single fraction
radiotherapy (SFRT) or multiple fraction radiotherapy (MFRT) de-
pending on the factors such as cancer type and presence of com-
plication within the bone [5–8]. Although the distribution of BoMGmbH. This is an open access art
lumbia Radiation Oncologist,
ge Street, Prince George, BC,
. Barnes),have been observed in many skeletal locations, BoM that are distal
to the elbow and knee joints are considered rare and therefore are
infrequently reported [9].
Depending on the primary tumour histopathology, the fre-
quency of skeletal bone metastases ranges from 10% to close to
90% and bone lesions are found more commonly within the axial
skeletal versus the appendicular skeleton [10]. Although any ske-
letal bone may be involved with metastatic disease, the vertebral
body is most commonly associated with metastatic disease; long
bone involvement or metastases distal to the elbow and knee are
rare [11–13]. This study sought to assess the incidence of distal
bone metastases treated with radiotherapy in a provincial
programme.2. Material and methods
All courses of RT for bone metastases from 2007 to 2011 for
patients living in BC were identiﬁed in a provincial RT programme.
The BC Cancer Agency (BCCA) Information System (CAIS) was used
to identify 8008 patients who received 16,277 palliativeicle under the CC BY-NC-ND license
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formation retrospectively collected on these patients included:
patient age, gender, primary tumour histology, fractionation
schedules, and location of bone metastases.
Treated BoM were categorized as distal if the BoM was located
within or distal to the elbow or knee. Patients were grouped by
primary tumour site as breast, lung, prostate gastrointestinal,
haematological, melanoma, and other. The incidence of distal bone
metastases and associations with primary tumour types were
determined.
Multivariable linear regression analysis was used to determine
associations between primary tumour type and incidence of distal
bone metastases. P values were two-sided, and values less than.05
were considered statistically signiﬁcant. We used the SPSS statis-
tical software package, version 19.0 (Chicago, IL), for data entry
and statistical analysis. This study was approved by the combined
BCCA and UBC Research Ethics Board.Fig. 1. SFRT utilisation when treating distal and non-distal BoM.
Table 2
Multi-variable linear analysis of distal BoM.
Characteristic Odds ratio to have
distal bone metas-
tases (41 favours
distal met)
95% con-
ﬁdence
interval
p Value
Age 0.99 0.98–1.00 0.07
Male 0.77 0.57–1.05 0.09
Tumour
Group
Prostate – – po0.001
Breast 0.54 0.32–0.90 0.02
Lung 0.95 0.63–1.44 0.82
Haematological 1.25 0.81–1.93 0.31
Gastrointestinal 0.40 0.19–0.83 0.40
Melanoma 2.76 1.38–5.53 0.004
Other 0.91 0.57–1.44 0.68
BCCA
Centre
Vancouver
Centre
– – po0.001
Abbotsford
Centre
2.37 1.54–3.64 0.001
Centre for the
Southern
Interior
0.91 0.65–1.32 po0.001
Fraser Valley
Centre
1.05 0.72–1.51 0.62
Vancouver Is-
land Centre
0.91 0.65–1.26 0.823. Results
From 2007 to 2011, 8008 patients in BC were treated with 16,
277 palliative radiotherapy courses; 425 (3%) of the courses pre-
scribed were used to treat bones located within or distal to the
elbow or knee. Male patients were treated more often than female
patients (52%) and SFRT was prescribed 49% of the time (Table 1).
Breast and lung malignancies were observed most commonly
(23%), followed by prostate (19%), other (15%), lymphoma (11%),
gastrointestinal (8%) and melanoma (1%) (Table 1). We demon-
strated that Melanoma malignancies resulted in the highest fre-
quency (5%) of distal BoM; followed by haematological (3%), lung
(2%) prostate (2%), other (2%), gastrointestinal (1%), and breast
(1%). Distal BoM where more commonly identiﬁed in the lower
extremity (87%, po0.001).
Distal BoM were treated with SFRT signiﬁcantly more often
than non-distal BoM (po0.001) (Fig. 1).
Table 2 presents the multi-variable analysis performed to de-
termine the associations between distal BoM and patient char-
acteristics, which demonstrated that patients with melanoma have
a signiﬁcant higher odds of having distal bone metastases
(p¼0.004). The regression analysis also showed signiﬁcant corre-
lation between having distal bone metastases treated at Abbots-
ford Centre (odds ratio 2.37, 95% conﬁdence interval 1.54–3.64,
po0.0001) (Table 2).4. Discussion
This is the ﬁrst large scale study to illustrate the incidence of
distal bone metastases in patients being treated with palliative
radiotherapy (RT). From 2007 to 2011, 16,277 courses of palliativeTable 1
Patient characteristics.
Characteristic Proportion (n¼16,277)
Male 52%
Tumour group Prostate (n¼3103) 19%
Breast (n¼3687) 23%
Lung (n¼3716) 23%
Lymphoma (n¼1860) 11%
Gastrointestinal (n¼1277) 8%
Melanoma (n¼299) 1%
Other (n¼2405) 15%
Distal metastases (n¼425) 3%
Single fraction radiotherapy (n¼8004) 49%RT was used to treat bone metastases in 8008 patients; 425 (3%) of
which were RT courses for distal BoM. In addition, distal bone
metastases were signiﬁcantly more likely to be treated with SFRT.
This population-based study demonstrates that patients with
melanoma have the highest proportion of distal BoM. This differs
from previous reports, which only present that prostate, breast,
and lung cancer have the highest absolute number of distal BoM,
likely because these are the most common cancers with any type
of BoM [9,14–17]. Here we showed that SFRT was used to treat
distal BoM more often than non-distal BoM (66% versus 49%, re-
spectively), likely because distal BoM are located in regions that do
not contain organs at risk such as the spinal cord [18].
This study should be considered in the context of its strengths
and weaknesses. A weakness of this study is that untreated BoM
are not captured, and therefore the incidence of distal BoM may be
under-represented. However, it is unlikely that the proportion of
distal BoM is markedly different than reported. In addition, the
large population-based nature of this study provides adequate
power to identify correlations between distal BoM and primary
tumour type, while being relatively free of selection bias.
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This population based study identiﬁed an incidence of distal
BoM of 3% among patients treated with palliative RT. The in-
cidence of distal BoM was signiﬁcantly more common with mel-
anoma and haematological malignancies.Conﬂict of interest notiﬁcation
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